1 / 1

CBNPC ALK+, activité antitumorale sur les lésions cibles (n = 34)

CBNPC ALK+, activité antitumorale sur les lésions cibles (n = 34). Meilleure réponse globale. Réponse complète. Progression. Stabilité. Réponse partielle. Taux de réponse : 65 % (22/34) [IC 95 : 47-80] Post- crizotinib : 61 % (19/31) [incl. 1 criz intolérant]

garth
Download Presentation

CBNPC ALK+, activité antitumorale sur les lésions cibles (n = 34)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CBNPC ALK+, activité antitumorale sur les lésions cibles (n = 34) Meilleure réponse globale Réponse complète Progression Stabilité Réponse partielle Taux de réponse : 65 % (22/34) [IC95 : 47-80] Post-crizotinib : 61 % (19/31) [incl. 1 criz intolérant] Naïf d’ITK : 100 % (3/3) [Incl. 1 CR] 40 20 0 -20 Variation des lésions cibles (%) -40 -60 -80 -100 • ESMO 2013 – D’après Camidge DR et al., abstr. 3401, actualisé

More Related